dihomo γ linolenic acid

Dihomo-γ-linolenic acid (DGLA; all-cis-8,11,14-Eicosatrienoic acid) sodium, a 20-carbon ω-6 fatty acid, exhibits anti-inflammatory and anti-proliferative properties. It has been shown to mitigate atherosclerosis in the apolipoprotein E deficient mouse model system [1] [2] [3].

Ethyl dihomo-γ-linolenic acid ethyl ester (ethyl DGLA), an ω-6 fatty acid intermediate ester form, elevates prostaglandin E1(PGE1) and PGE2 secretion in rabbit renal papilla when administered dietarily at a dosage of 1 g/kg per day for 25 days. Additionally, this dosage of ethyl DGLA increases triglyceride levels and enhances the proportion of 20:3ω6 and 20:4ω6 phospholipids in the renal medulla of rabbits. Ethyl DGLA formulations have been employed in managing eczema and inflammatory disorders.

Dihomo-γ-Linolenic acid methyl ester is the methyl ester form of Dihomo-γ-Linolenic acid which has anti-inflammatory and anti-proliferative effects.

Dihomo-γ-linolenic acid (DGLA) is a fatty acid widely found in plants with antitumor and antiproliferative effects, inhibits the growth of xenograft tumor cells, and can be used in the study of inflammation-related diseases such as rheumatoid arthritis, atherosclerosis, and atopic dermatitis.

α-Linolenic Acid (ALA) is an essential fatty acid that cannot be synthesized by the human body and is obtained by isolating it from seed oils. α-Linolenic acid has been shown to improve memory, inhibit thrombosis, and lower blood lipids.

γ-Linolenic acid ethyl ester (Ethyl γ-linolenate) is a leukotriene B4 receptor 4 (LTB4) antagonist with potential anti-inflammatory effects[1].

α-Linolenic acid (ALA) is an essential fatty acid found in leafy green vegetables. ALA, as part of a low saturated fat diet, helps prevent cardiovascular disease. ALA decreases blood pressure, serum cholesterol levels, and platelet aggregation.

gamma-Linolenic acid (gamolenic acid), is an unsaturated fatty acid synthesized from linoleic acid (LA) by the enzyme delta-6-desaturase. Research on hepatocellular cell lines has shown γ-Linolenic Acid to have induced reactive oxygen species generation including lipid peroxidation, cell growth inhibition, and heme oxygenase-1 production for antioxidant protection against oxidative stress. Further experiments have noted that γ-Linolenic acid inhibits inflammatory responses through inactivation of NFκB and activator protein-1 by suppressed oxidative stress.

γ-Linolenic Acid methyl ester (Methyl gamma-linolenate) is a weak leukotriene B4 (LTB4) receptor antagonist.

Prostaglandin F1α (PGF1α) is the putative metabolite of dihomo-γ-linolenic acid (DGLA) via the cyclooxygenase (COX) pathway. Both PGF1α and PGF2α have been shown to act as priming pheromones for male Atlantic salmon with a threshold concentration of 10-11 M. [1] PGF1α binds to the ovine corpus luteum FP receptor at only 8% of the relative potency of PGF2α. [2] It is only half as active as PGF2α in inducing human respiratory smooth muscle contractions in vitro. [3]

12(S)-HETrE is produced by 12-lipoxygenase oxidation of dihomo-γ-linolenic acid (DGLA). 12(S)-HETrE is reported to inhibit agonist-mediated platelet activation (IC50 = 40 μM), α granule secretion, integrin αIIbβ3 activation, Rap1 activation, and thrombin-induced clot retraction in vitro.

8,11,14-Eicosatrienoic acid, also known as dihomo-γ-linolenic acid , is a polyunsaturated fatty acid (PUFA) produced from γ-linolenic acid by the action of fatty acid elongases. It can be metabolized by the cyclooxygenase pathway to produce 1-series prostaglandins (PGs) (e.g., PGE1). (±)14(15)-EpEDE is an EpEDE acid formed from 8,11,14-eicosatrienoic acid. This monoepoxide can be generated from the PUFA, in vitro, by the action of a strong oxidizing agent. Alternatively, this compound may be produced, in vivo, by epoxidation of the PUFA by cytochrome P450 epoxygenases. The biological properties of this compound are poorly understood.

15(S)-HETrE is the hydroxy-trienoic acid resulting from 15-lipoxygenation of dihomo-γ-linolenic acid. It inhibits 5-LO in human PMNL with an IC50 value of 4.6 μM. In RBL cells, 15(S)-HETrE also inhibits 5-LO, but is approximately 1 20 as potent as 15(S)-HpETE.

Prostaglandin D1 (PGD1) is the theoretical D-series metabolite of dihomo-γ-linolenic acid (DGLA), but to date it has not been isolated as a natural product. It is an inhibitor of ADP-induced platelet aggregation in humans with an IC50 value of 320 ng/ml, about 1/10 as potent as PGD2. 13,14-dihydro-15-keto Prostaglandin D1 (13,14-dihydro-15-keto PGD1) is the theoretical metabolite of PGD1 via the 15-hydroxy PG dehydrogenase metabolic pathway. No biological studies for this compound have been reported.

8(S)-HETrE is a monohydroxy polyunsaturated fatty acid produced by rabbit neutrophil lipoxygenase when dihomo-γ-linolenic acid is used as a substrate. Although the biological activities of 8(S)-HETrE have not been well characterized, it is expected to behave similarly to 8(S)-HETE .

Prostaglandin E1 (PGE1), synthesized through cyclooxygenase-mediated metabolism of dihomo-γ-linolenic acid (DGLA), functions by inhibiting platelet aggregation (IC50= 40 nM) and enhancing vasodilation. Its analog, 13,14-dihydro-16,16-difluoro PGE1, and the metabolite, 13,14-dihydro PGE1, both retain similar anti-aggregatory properties to the original compound. The inclusion of two electron-withdrawing fluorine atoms in 13,14-dihydro-16,16-difluoro PGE1 is believed to increase molecular stability and potentially extend bioavailability by resisting hydrolytic degradation.